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Abstract
Background: PI3K/AKT signalling pathway is aberrantly active and plays a critical role for cell cycle progression of human
malignant pleural mesothelioma (MMe) cells. AKT is one of the important cellular targets of perifosine, a novel bio-
available alkylphospholipid that has displayed significant anti-proliferative activity in vitro and in vivo in several human
tumour model systems and is currently being tested in clinical trials.
Methods: We tested Perifosine activity on human mesothelial cells and different mesothelioma cell lines, in order to provide
evidence of its efficacy as single agent and combined therapy.
Results: We demonstrate here that perifosine, currently being evaluated as an anti-cancer agent in phase 1 and 2 clinical
trials, caused a dose-dependent reduction of AKT activation, at concentrations causing MMe cell growth arrest. In this study
we firstly describe that MMe cells express aside from AKT1 also AKT3 and that either the myristoylated, constitutively active,
forms of the two proteins, abrogated perifosine-mediated cell growth inhibition. Moreover, we describe here a novel
mechanism of perifosine that interferes, upstream of AKT, affecting EGFR and MET phosphorylation. Finally, we demonstrate
a significant increase in cell toxicity when MMe cells were treated with perifosine in combination with cisplatin.
Conclusions: This study provides a novel mechanism of action of perifosine, directly inhibiting EGFR/MET-AKT1/3 axis,
providing a rationale for a novel translational approach to the treatment of MMe.
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Introduction
Malignant Pleural Mesothelioma (MMe) is a rapidly lethal
cancer associated with exposure to asbestos that is increasing in
incidence worldwide [1,2]. Since MMe is resistant to conventional
therapies, the prognosis of these patients is poor, with a median
survival of 11–12 months after diagnosis [3,4] therefore, there is an
urgent need for effective therapy.
Activation of multiple receptor tyrosine kinases (RTKs) is critical
for cell proliferation and/or survival of MMe cells. Among RTKs,
MET and EGFR were thought to be two of the most significantly
involved in MMe proliferation and/or survival via PI3-K/AKT
signalling cascade activation. However, a phase II clinical study of
erlotinibtreatmentdidnotshowaneffectonMMe,although96%of
the specimens showed positive pEGFR [5].
The lack of EGFR mutation in MMe may be one of the reasons
for the unresponsiveness [6]. MET is another RTK which
mediates the activation of several signalling pathways, including
phosphoinositide 3-kinase (PI3-K)/AKT and Ras/mitogen-acti-
vated protein kinase cascades [7]. Previous studies demonstrated
that MET was expressed and activated in the majority of MMe
cell lines and clinical specimens [8,9]. However, MET inhibition
caused growth arrest in only a small subset of MMe cell lines,
regardless of frequent MET activation [10]. In a recently
published paper Kawaguchi et al. suggested that inhibition of
multiple RTKs may serve to develop a more effective target
therapy for patients with MMe [11].
As in other cancers among the RTKs activated signals, the
phosphoinositide 3-kinase (PI3K)/AKT pathway, plays a critical
role for the cell cycle progression in human MMe cells [12,13]. It
has been reported that inhibition of the PI3K activity led to
significant cell cycle arrest and suppression of cell proliferation of
different MMe cell lines [14]. PI3K activation results in
accumulation of phosphatidylinositol 3,4,5-trisphosphate and
phosphatidylinositol 3,4-bisphosphate [15]. Then pleckstrin ho-
mology (PH) domain-containing proteins including PDK1 and
AKT [16,17] bind to the 39-OH phosphorylated phosphatidyli-
nositols through this domain. This binding results in targeting of
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conformation for AKT Thr308 and Ser473 phosphorylation [18].
The first-generation of PI3K inhibitors include LY294002 and
wortmannin, both targeting the catalytic site of p110, which have
been used as research tools to elucidate the value of PI3K as
therapeutic target [19]. For the un-favourable pharmaceutical
properties, toxicity, and cross-over inhibition of other lipid and
protein kinases, they were not extensively used in clinical trials [20].
Perifosine [octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate]
is a synthetic novel alkylphospholipid (ALP), a new class of
antitumor agents which targets cell membranes of active pro-
liferating cells and inhibits PH domain mediated AKT membrane
recruitment and activation. Importantly, perifosine does not
directly affect either activity of PI3K or phosphoinositide-
dependent kinase 1 (PDK1) [21]. Perifosine has displayed
significant anti-proliferative activity in vitro and in vivo in several
human tumour model systems and is currently being tested in
different clinical trials [22,23].
The current study investigates a potential antitumor activity of
perifosine using in vitro MMe cell models, using perifosine either on
its own or in combination with established chemotherapeutic
drugs. We demonstrate that perifosine inhibiting both MET and
EGFR activation even in presence of HGF and EGF decreases
AKT phosphorylation and blocks cell proliferation without
inducing apoptosis of MMe cell lines. In this study we firstly
describe that MMe cells express aside from AKT1 also AKT3 and
that the perifosine induced cell growth inhibition were restored by
transfection of both myristoylated-AKTs, constitutively localized
to the plasma membrane. Moreover, co-treatment with perifosine
substantially increases cytotoxic effect of cisplatin in MMe cells.
Results
Perifosine targets AKT phosphorylation and affects MMe
cell proliferation inducing a G2/M phases arrest
Perifosine has a similar structure to naturally occurring
phospholipids that has been described to primarily interfere with
membranes of proliferating cells like tumour cells, Here we
demonstrate that 50% of Perifosine-induced MMe growth in-
hibition (IC50) in 24 hours was 23 mM, 14 mM and 7.5 mM for
REN, MSTO211H, and MMP respectively, while minimal
toxicity was displayed in HMC normal mesothelial cells
(Figure 1A). These doses were in line with achieved plasma
concentrations in vivo (described to be around 16 mM). The AKT
pathway is a target for the anti-proliferative effect of perifosine, so
we investigated the effect of this drug on the phosphorylation
status of AKT. Figure 1B shows that exposure of MMe cells to
perifosine for 1 hour caused a dose dependent loss of Ser473
phosphorylation of AKT, without affecting the total amount of the
protein. This loss of AKT phosphorylation was seen in all cell lines
tested at their IC50 concentration of perifosine. We elected REN
cells, representative of the more common epithelioid tumours, to
further characterize early signalling events affected by perifosine.
In REN cells we demonstrated that the treatment with different
doses of perifosine for 24 hours caused a cell cycle arrest with
a progressive significant accumulation in the G2/M phases
(Figure 2A). Both sub-G1 pick and cleavage of poly(ADP-ribose)
polymerase were not evident upon incubation with increasing
doses of perifosine for 24 h, indicating that no caspase dependent
apoptotic cell death occurred (Figure 2B). Moreover, the effects of
perifosine increased with time treatment leading all cells exposed
to 23 mM to die by 72 hours (Figure 2C). Similar results were
obtained on MSTO211-H cells (Figure S1).
A constitutive active form of AKT over-comes perifosine
inhibition
AKT comprises three closely related isoforms: AKT 1, AKT 2
and AKT 3, encoded by three different genes [24]. As the
phospho-antibody doesn’t discriminate between the three iso-
forms, in this study, AKT 1, AKT 2 and AKT 3 expression was
investigated in REN cells. Data reported in Figure 3A and 3B
show that REN cells express AKT1 and AKT3, while AKT2
mRNA was not evidenced (similar results on MSTO211-H cells
are shown in Figure S1).
Perifosine affects EGFR and MET signalling
Perifosine is similar to phospholipids, the main constituents of
cellular membranes and can modify membrane-related signal
transduction. Consistently in prostate cancer cells perifosine was
able to determine a reduction of AKT activity, cell proliferation,
and to induce apoptosis after stimulation with 50 ng/ml EGF,
although no data concerning EGFR activation were shown so far
[27]. Hence we analysed if perifosine could interfere with the
ligand mediated activation of EGFR and MET by immunopre-
cipitation and Western-blot experiments. As shown in Figure 4A
and 4C in REN cells starved, treated 1 hour with perifosine
(23 mM) and then stimulated 10 minutes with 5 ng/ml of EGF or
HGF both EGFR and MET were not phosphorylated even in the
presence of their ligands. Also EGFR and MET signalling were
significantly compromised; in fact also growth factor induced AKT
Figure 1. Effects of perifosine on cell viability and AKT
phosphorylation. A, effect of perifosine on the viability of HMC and
three different MMe cell lines (REN, MSTO211-H and MMP) after
24 hours treatment at the indicated concentrations. Points, means 6 SD
of three individual measurements. B, REN, MSTO211-H and MMP cells
were treated with the indicated doses of perifosine for 1 hour. Cells
were lysed, and equal amounts of protein were separated by SDS-PAGE,
transferred to nitrocellulose membrane, probed with phospho-specific
AKT and re-probed with panAKT antibodies as described in ‘‘Materials
and Methods.’’ Representative of three independent experiments.
doi:10.1371/journal.pone.0036856.g001
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models [26], analogous concentrations of perifosine actually
caused a slight increase in basal ERK1/2 phosphorylation, while
counteracted that induced by growth factors. The effect of
perifosine was also assessed on growth factor mediated cell
proliferation. As shown in Figure 4B and 4D, 23 mM perifosine
administered 24 hours to REN cells in the presence of EGF or
HGF abrogated growth factor induced cell proliferation. Of note
similar data were observed in the MSTO-211H cell line (Figure
S1). Moreover, perifosine was more effective than single or
combined usage of EGFR and MET specific inhibitors, either in
terms of cell viability than of AKT activation (data not shown).
Perifosine enhances response of MMe cells to
chemotherapeutic agents
To determine the nature of interactions between perifosine and
chemotherapeutic agents currently used in the MMe therapy, we
examined data from dose–response curves by isobologram
Figure 2. Effect of perifosine on REN cell cycle progression. A,
REN cells were treated with different doses of perifosine for 24 hours.
After treatments, cells were stained with propidium iodide as described
in ‘‘Materials and Methods’’ and analysed for cellular DNA content by
flow cytometry. Data reported in the table represent mean 6 SD (n=3)
of the percentage of cells in each phase of the cell cycle, * p#0.005,
**p#0.001. B, REN, cells were treated with the indicated doses of
perifosine for 24 hours. Cells were lysed, and equal amounts of protein
were separated by SDS-PAGE, transferred to nitrocellulose membrane,
probed with a specific anti-PARP1 antibody and tubulin for equal
loading. Representative of three independent experiments. C, Effect of
perifosine on the viability of REN cells was tested at 24, 48 and 72 hours
treatment at the indicated concentrations. Points, means 6 SD of three
individual measurements.
doi:10.1371/journal.pone.0036856.g002
Figure 3. Expression of AKTs and rescue of perifosine effects
by transfection with constitutive active Myr-AKTs. A, AKT1, 2, 3
and actin as control mRNA expression in A549 and REN cells was
evaluated by RT-PCR as reported in in ‘‘Material and Methods’’ section.
B, AKT1 and 3 protein expression was evaluated by Western blot
analysis in REN cells with isoform specific antibodies, tubulin blot
confirmed equal loading. Representative of three independent experi-
ments. C, REN cells were transfected with 1 mg/plate of plasmid coding
for the constitutive activated form of AKT, Myr-AKT1 or 3. 24 hours post
transfection REN cells were treated with 23 mM perifosine for 1 hour,
then were lysed and equal amounts of proteins were subjected to SDS-
PAGE followed by immuno-blotting with specific antibodies to
phosphorylated AKT, HA to confirm transfection and tubulin for equal
loading. D, The effect of perifosine on cells transfected with Myr- AKT1
or 3 was also assessed on cell proliferation. REN cells were transfected
with 1 mg/plate of plasmid coding Myr-AKT1 or 3 and 24 hours post
transfection were treated with 23 mM perifosine for 24 hours. At the
end of treatment viable cell count was determined. Points, means 6 SD
of three individual measurements. Perifosine markedly alters AKT
membrane translocation, so we next asked whether forced expression
of an exogenous Myr-AKT1 or Myr-AKT3 could abrogate the effect of
perifosine on AKT activating phosphorylations and cell growth.
Contradictory data are available in literature on the capability of
a constitutively active AKT to overcome perifosine action. While in
prostate cancer cells inhibition of AKT phosphorylation was sub-
stantially relieved by introduction of a Myr-AKT1, which bypassed the
requirement for PH domain-mediated membrane recruitment, in
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IC50 for single drug effects that were determined experimentally,
using the data from the dose-response experiments as a starting
point. Perifosine (from 5 to 20 mM) and cisplatin (IC50: 100 mM)
or pemetrexed (IC50: 22 mM) or gemcitabine (IC50: 2 nM) were
administered simultaneously for 24 hours to REN cells in colture.
At the end of incubation cells were trypsinized and counted.
Representative isobolograms in Figure 5 indicate that the
combination of perifosine and cisplatin displayed strong synergistic
cytotoxicity in REN cells across a broad range of doses. Moreover,
perifosine showed additivity in combination with gemcitabine
while it seemed to antagonize the effect of pemetrexed. Sinergy
with cisplatin is also reported in the MSTO-211H cell line (Figure
S1) even if different sensitivity to drugs was observed.
Discussion
PI3-K/AKT signalling has been demonstrated to have a crucial
biologic impact in MMe cell-cycle regulation, anti-apoptosis and
chemo-resistance. Activation of AKT, as reported by Altomare et
al., was observed in 65% of MMe specimens even if genetic
alterations seemed to be infrequent for PI3-K/AKT activation in
MMe cells [12].
Moreover, phospho-RTK array analysis showed that in MMe
cells the EGFR family, EGFR, ErbB2 or ErbB3, was frequently
co-activated with MET, which suggested that MET and EGFR
family activation may compensate each other for the persistent
downstream signalling activation [28]. In fact, as reported in
several studies, even if EGFR and MET were highly expressed in
MMe, single RTK inhibitors applied in phase II trials were not
sufficient to inhibit MMe cell proliferation, suggesting that
inhibition of multiple RTKs may serve to develop a more effective
target therapy for patients with MMe in the future [28].
Consideration of PI3K/PDK1/AKT signalling pathway, as
a point of convergence of growth factor-related effects on cell
proliferation, as a potential new target for MMe therapy, led to the
experiments reported here.
Perifosine [octadecyl-(1,1-dimethyl-piperidinio-4-yl)-phosphate]
is a synthetic novel alkylphospholipid, a new class of antitumor
agents which targets cell membranes, inhibits AKT activation, and
induces apoptosis in different carcinoma cells.
The experiments presented in this paper demonstrate that
perifosine, caused inhibition of MMe cell growth (IC50 by 7.5 mM
to 23 mM in 24 hours) and cell cycle arrest at G2-M phase,
associated with rapidly decreased AKT activation, as assessed by
Ser473 phosphorylation quantification. As preferentially acting on
the membrane structure of active proliferating cells, perifosine
resulted only slightly toxic on normal mesothelial cells.
The AKT family has three highly homologous isoforms: AKT 1,
AKT2andAKT3,encodedbythreedifferentgenes.AllthreeAKT
proteins contain an N-terminal pleckstrin homology(PH) domain,
a catalytic kinase domain and a C-terminal regulatory domain.
As the phospho-specific and the anti AKT antibodies we used
don’t discriminate between the three isoforms, we more deeply
investigated their expression in our cells. We firstly describe that
MMe cells express AKT1 and AKT3 and that perifosine interferes
with both. Considering the tumorigenesis potential of AKT
isoforms, further study on function of them in MMe are needed.
Inhibition of AKT phosphorylation and cell proliferation were
substantially relieved by introduction of a constitutive active
myristoylated AKT1 or 3, which bypassed the requirement for PH
domain-mediated membrane recruitment, supporting the hypoth-
esis that perifosine does not directly affect activity of PI3-K or
phosphoinositide-dependent kinase 1 (PDK1). It has been reported
that perifosine enhances the antitumor activity of cetuximab in
PTEN-deficient cancer cells and that the combination treatment
enhancedtheinhibitionofphosphorylationofAKT,p44/42MAPK
and p38MAPK, but offset the phosphorylation of SAPK/JNK that
was activated by perifosine treatment alone [29]. Moreover, it has
been described that perifosine showed synergistic effects with
erlotinibrestoringtheefficacyagainstEGFRinhibitorsinPCa[28].
Importantly, when we analysed more deeply the response of
MMe cells to EGF and HGF we observed that perifosine, probably
acting on cell membrane structure or affecting receptor interactions
or recruitment of co-activators, abrogated upstream to signalling
molecules both EGFR and MET ligand induced phosphorylation.
Finally we tested the effects of combined therapy with perifosine
and cisplatin or pemetrexed or gemcitabine using the isobologram
analysis. As evidenced by our results perifosine clearly synergized
with cisplatin treatment and exerted an additive effect with
gemcitabine.
In summary, we have highlighted AKT, a multifunctional
kinase, whose activation is associated with resistance to cell death
and tumorigenesis, as an important target of perifosine. We have
demonstrated here that perifosine inhibits either AKT1 than
AKT3 phosphorylation and activation in cells growing exponen-
tially in serum-containing medium and after growth factor
stimulation. This latter mechanisms provide a novel rationale to
consider perifosine also as a multi-target inhibitor, whereas
interference with the proper membrane localization of target
proteins for their phosphorylation and activation (instead of direct
inhibition of the phosphotransferase activity of the kinases known
to regulate AKT), seems to be a further novel mechanism of the
drug’s action we disclose here. Although the efficacy of combined
treatment between cisplatin and perifosine must be validated by
further in vivo studies, our results underline perifosine as a multi-
target therapy for MMe. More interestingly, perifosine was already
shown to give partial response and stable disease in patients in
second line therapy (unpublished data kindly provided by Keryx
Biopharmaceutical).
Materials and Methods
Cell cultures treatments and transfection
The epithelioid MMe derived REN cell line that was used as the
principal experimental model in this investigation was kindly
provided by Dr. S.M. Albelda (University of Pennsylvania,
Philadelphia, PA), MMP were stabilized from pleural effusions
of malignant mesothelioma patients [30] and primary HMC-
TERT cultures obtained from patients with congestive heart
failure and immortalized by expression of a human telomerase
subunit [31]. The biphasic derived MSTO-211H cell line was
obtained from the Istituto Scientifico Tumori (IST) Cell-bank,
Genoa, Italy. Cells were cultured in standard conditions.
Cells grown to 80% confluence in tissue culture dishes were
transiently transfected with pcDNA3 Myr-HA-AKT1 or pBABE
myeloma cells it has been described that perifosine overcome
constitutive highly active AKT1 [25,26]. We transiently transfected REN
cells either with an HA-tagged Myr-AKT1 or Myr-AKT3 and treated them
for 24 hours with the IC50 dose of perifosine. Western-blot analysis
reported in Figure 3C shows that transfection of both Myr-AKT1 and
Myr-AKT3 overcomes perifosine inhibition of AKT phosphorylation in
REN cells; only a slight reduction of phosphorylation, probably due to
the block of the endogenous proteins, was observed. Cell growth
analysis reported in Figure 3D demonstrates that both transfected Myr-
AKTs rescued perifosine induced block of cell proliferation.
doi:10.1371/journal.pone.0036856.g003
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tutively active form of AKTs from Addgene by the LipofectA-
MINE reagent as described by the manufacturer.
Reagents and antibodies
The monoclonal antibodies specific for phospho tyrosine,
phospho-ERK1 (pThr202 and pTyr204) and ERK2 (pThr185
and pTyr187) MAP kinases, and phospho-Akt (pSer473) AKT1
and AKT3, were from Cell Signaling Technology (Beverly, MA).
The antibodies specific for a-tubulin, PARP1, ERK1/2, panAKT,
MET, EGFR and HA were from Santa Cruz Biotechnology
(Santa Cruz, CA). Anti mouse and anti rabbit IgG peroxidase
conjugated antibodies, growth factors and chemical reagents were
from Sigma–Aldrich (St Louis, MO). ECL was from Amersham
Pharmacia Biotech (Uppsala, Sweden). Nitrocellulose membranes
and protein assay kits were from Bio-Rad (Hercules, CA). Culture
Figure 4. Effects of perifosine on EGFR and MET phosphorylation and signalling. A, B, Exponentially growing REN cells were pre-treated
with 23 mM perifosine for 1 hour and then incubated 10 minutes with EGF (5 ng/ml) or HGF (5 ng/ml). At the end of experiment, cell lysates were
prepared or immunoprecipitated and analyzed by immunoblotting with indicated antibodies. Results are representative of three different
experiments. B, D, The effect of perifosine was also assessed on growth factor mediated cell proliferation. REN cells were treated with 23 mM
perifosine 24 hours in the absence or in the presence of 5 ng/ml EGF or HGF. At the end of treatment viable cell count was determined. Points, means
6 SD of three individual measurements.
doi:10.1371/journal.pone.0036856.g004
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(Carlsbad, CA). Perifosine is marketed and kindly provided by
Keryx Biopharmaceutical (New York, NY).
Cell lysis, immunoprecipitation and immunoblot
Proteins were extracted and immunoprecipitated and SDS-
PAGE separated as previously described [32]. Following SDS-
PAGE, proteins were transferred to nitrocellulose, reacted with the
indicated specific antibodies and then detected with horseradish
peroxidase-conjugated secondary antibodies and the chemiolumi-
nescent ECL reagent. Densitometric analysis was performed using
the GS 250 Molecular Imager (Bio-Rad).
Cell proliferation as determined by direct counting
MMe cellsweregrownand treatedincompletemediumasabove
indicated, then were trypsinized and stained with Trypan blue. The
number of viable cells was counted in a Burker chamber.
Cell Cycle Analysis
Cell cycle/apoptosis analyses were performed using propidium
iodide staining with subsequent FACS analysis. 5610
5 cells/well
were cultured on tissue culture plates with or without treatment for
24 hours. After incubation, adherent cells were detached with
trypsin (0.5% trypsin/0.1% EDTA in PBS). Detached and
suspended cells were harvested in complete DMEM medium and
centrifuged at 500 g for 10 minutes. Pellets were washed with PBS
and fixed with ice cold 75% ethanol overnight at 4uC, treated with
100 mg/ml RNAse A, and subsequently stained with 25 mg/ml
propidium iodide. Then they were analyzed by using a flowcyt-
ometer FACS (Becton Dickinson, Franklin Lakes, NJ) and Modfit
software (Verity Software House, Inc., Topsham, Maine).
RNA isolation and RT-PCR
Total RNA was extracted from REN, MSTO-211H and A549
cell lines subsequent to the Trizol Reagent (Life Technologies, Inc.)
protocol. The quality and quantity of the RNA was determined by
measuring the absorbance of the total RNA at 260 and 280 nm. To
obtain cDNA was used RevertAid cDNA Synthesis Kit from
Fermentas. Primers for Akt isoform expression were described by
Okanoetal.[33]andweresynthesizedbyMWG.Theprimerswere:
59-GCTGGACGATAGCTTGGA-39 (Akt1 sense); 59-GATGA-
CAGATAGCTGGTG-39 (Akt1 antisense); 59-GGCCCCTGAT-
CAGACTCTA-39 (Akt2 sense); 59-TCCTCAGTCGTGGAG-
GAGT-39 (Akt2 antisense); 59-
GCAAGTGGACGAGAATAAGTCTC-39 (Akt3 sense); and 59-
ACAATGGTGGGCTCATGACTTCC-39 (Akt3 antisense). b-
Actin primers were 59-GTGGGGCGCCCCAGGCACCA-39
(sense) and 59-CTCCTTAAGTCACGCACGATTTC-39 (anti-
sense). RT-PCR reactions was performed using 2xPCR Master
Mix from Fermentas according standard procedures. The PCR
products were electrophoresed on a 1% agarose gel and visualized
with ethidium bromide. The Akt primers were designed to generate
3832 (Akt1), 2762 (Akt2), and 3292 (Akt3) bp products,
respectively.
Statistical and Isobologram analysis
Data are expressed as the mean 6 SEM. Differences between
values obtained in a population of cells treated with different
experimental conditions were determined using the unpaired t-
Figure 5. Isobologram analysis of drug interactions. A, B, C,
Isobologram plots of the interactions between perifosine and cisplatin
or gemcitabine or pemetrexed compounds on REN cells. Cells (5610
4)
were plated in complete medium and allowed to adhere to the surface
overnight. The plating medium was removed and replaced with
medium containing various concentrations of perifosine and the IC50
doses of the other drugs. To determine the nature of the interaction
between perifosine and cis-platinum or gemcitabine or pemetrexed, we
counted surviving cells following 24 hours drug incubation. The
diagonal line represents the isoeffect line of additivity. Each point is
the mean determined from experiments performed in triplicate.
doi:10.1371/journal.pone.0036856.g005
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The theoretical basis of the isobologram method has been
described in previous studies [34,35].
Based on the dose–response curves of cisplatin, pemetrexed and
gemcitabine, three isobolograms were constructed by plotting the
IC50 values of the single drugs on the y and of perifosine on the x
axes respectively, and the theoretical additive dose combination
was calculated.
Supporting Information
Figure S1 Analysis of perifosine effects on MSTO-211H
cells. A, effect of perifosine on the viability of MSTO-211H cells
at 24, 48 and 72 hours treatment at the indicated concentrations.
Points, means 6 SD of three individual measurements. B,
Exponentially growing MSTO-211H cells were pre-treated with
20 mM perifosine for 1 hour and then incubated 10 minutes with
EGF (5 ng/ml) or HGF (5 ng/ml). At the end of experiment, cell
lysates were prepared and analyzed by immunoblotting with
indicated antibodies. Results are representative of three different
experiments. C, AKT1, 2 and 3 and actin, as control, mRNA
expression in MSTO-211H cells was evaluated by RT-PCR as
reported in ‘‘Material and Methods’’ section. D, Isobologram plot
of the interactions between perifosine and cisplatin on MSTO-
211H cells.
(TIF)
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